Date Title  
Nov 11, 2021
Summary ToggleSol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
 
Nov 09, 2021
Summary ToggleSol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
 
Nov 04, 2021
Summary ToggleSol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
 
Sep 22, 2021
Summary ToggleSol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
 
Sep 09, 2021
Summary ToggleSol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference
 
Aug 04, 2021
Summary ToggleSol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
 
Jul 27, 2021
Summary ToggleSol-Gel Technologies Announces FDA Approval of TWYNEO®
 
Jul 20, 2021
Summary ToggleSol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
 
Jun 28, 2021
Summary ToggleSol-Gel Announces Pipeline Update and Future Development Plans
 
Jun 28, 2021
Summary ToggleSol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
 
Displaying 11 - 20 of 88 results